Chronic spontaneous urticaria (CSU) is a benign skin disorder usually responsive to treatment; however, at times it can be difficult to control and become very debilitating. We discuss the case of a woman with CSU that was unresponsive to H1-Antihistamines who was treated with omalizumab and became pregnant during omalizumab treatment. We also considered the follow-up of the mother and newborn for 4 years after delivery. Our case report confirms that omalizumab is a safe and effective therapeutic option, after careful evaluations in terms of cost-effectiveness, in pregnant and lactating women with severe chronic urticaria. Assessment throughout follow-up confirmed a regular progression of pregnancy parameters and no adverse reaction was documented in the child from birth to 4 years of age.

Omalizumab use in chronic spontaneous urticaria during pregnancy and a four years' follow-up : a case report / L.M. Losappio, C. Mirone, J.W. Schroeder, J. Scibilia, L. Balossi, E.A. Pastorello. - In: CASE REPORTS IN DERMATOLOGY. - ISSN 1662-6567. - 12:3(2020), pp. 174-177.

Omalizumab use in chronic spontaneous urticaria during pregnancy and a four years' follow-up : a case report

Balossi L.;Pastorello E. A.
2020

Abstract

Chronic spontaneous urticaria (CSU) is a benign skin disorder usually responsive to treatment; however, at times it can be difficult to control and become very debilitating. We discuss the case of a woman with CSU that was unresponsive to H1-Antihistamines who was treated with omalizumab and became pregnant during omalizumab treatment. We also considered the follow-up of the mother and newborn for 4 years after delivery. Our case report confirms that omalizumab is a safe and effective therapeutic option, after careful evaluations in terms of cost-effectiveness, in pregnant and lactating women with severe chronic urticaria. Assessment throughout follow-up confirmed a regular progression of pregnancy parameters and no adverse reaction was documented in the child from birth to 4 years of age.
urticaria; pregnancy; omalizumab
Settore MED/09 - Medicina Interna
CASE REPORTS IN DERMATOLOGY
Article (author)
File in questo prodotto:
File Dimensione Formato  
Losappio_Pastorello_Case Report in Dermat_2020 Ind publ.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 200.06 kB
Formato Adobe PDF
200.06 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/779270
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact